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ABSTRACT
Background. In the future, an increasing number of female liver transplant recipients
will reach the climacteric with osteoporosis as a common complication. We evaluated the
factors associated with decreased bone mass among women after liver transplantation.
Methods. A prospective, cross-sectional study of 23 outpatient transplant recipients
followed from February 2009 to March 2010 included women of age 35 years after
liver transplantations 1 year prior. We recorded patient histories, liver enzyme levels,
as well as bone mineral densities measured at the lumbar spine and femur. Statistical
analysis used Fisher’s exact test, simple odds ratio (OR), and Spearman’s rank
correlation coefficient.
Results. The mean patient age was 52.5  11 years with 30.4% premenopausal, and
69.6% perimenopausal or postmenopausal. Approximately 21% showed osteoporosis and
35%, a low bone mass. Postmenopausal women: OR 69.0 (95% CI 2.89–1647.18; P 
.0001), aged 49 years: OR 13.33 (95% CI 1.78–100.15; P  .0123) and receiving a
transplant after 44 years of age: OR 49.50 (95% CI 3.84–638.43; P  .0001) were
associated with a lower bone mass. Having undergone transplantation for more than 5.8
years lowered the risk of bone mass change: OR 0.11 (95% CI 0.02–0.78; P  .0361).
Clinical and laboratory variables, including corticosteroid use, were not associated with
decreased bone mass.
Conclusion. Understanding the prevalence and factors associated with osteoporosis
among female liver transplant recipients is important to enhance the strategies to diagnose
and treat these women, seeking to improve their quality of life.
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fIN THE LAST few decades, liver transplantation hasbecome widely accepted as an established form of
therapy worldwide. Considerable progress in clinical trans-
plantation has produced good long-term results, resulting in
a significantly increased survival of patients who experience
severe liver disease.1 Despite improved survival, their mor-
bidity has been known to increase, impairing quality of life
among transplant recipients.2 Women represent approxi-
mately one third of liver transplant patients. Their major
indications for liver transplantation include primary biliary
cirrhosis, posthepatitis cirrhosis, and autoimmune hepati-
tis.3 In Brazil, transplantation is mainly indicated for hep-
atitis virus C and alcoholism.4 Osteoporosis is a severe
complication after liver transplantation. As a result of
preexistent chronic liver disease and the high doses of
immunosuppressive agents, the majority of liver transplant
patients show accelerated loss of bone mass within the first
© 2011 Published by Elsevier Inc.
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Transplantation Proceedings, 43, 1351–1356 (2011)or 6 months after surgery, resulting in a greater fracture
isk.5 Other factors such as vitamin D deficiency, hypogo-
nadism, malnutrition, and reduced physical activity, which
are common among patients with end-stage liver disease,
also contribute to decreased bone mineral density.6 Chole-
tatic diseases such as primary biliary cirrhosis and primary
clerosing cholangitis have also been identified as risk
actors for changes in bone mass, perhaps owing to malab-
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1352 BACCARO, BOIN, PEDRO ET ALsorption of calcium and vitamin D, as well as to interference
of hyperbilirubinemia with osteoblast function.7
In addition to all of the factors associated with liver
transplantation, climacteric women have a greater decrease
in serum levels of estrogen. However, a previous study
identified age and severity of liver disease, and not meno-
pausal status, as the main risk factors for the development
of osteoporosis among women with primary biliary cirrhosis
who did not undergo liver transplantation.8
In the future, an increasing number of women undergo-
ing liver transplantation will reach the climacteric. How-
ever, there are relatively few studies related to hypogonad-
ism after liver transplantation. The existing reports are
often limited to the male population.9 With the purpose of
dentifying possible risk factors associated with bone mass
hanges in liver transplant recipients and enhancing the
trategy for managing osteoporosis among these patients,
e performed a study of women who had undergone liver
ransplantation.
METHODS
This prospective, cross-sectional study included female liver trans-
plant recipients followed from February 2009 to March 2010. All
women aged35 years who had received a liver transplant1 year
prior were included in the study. Women with amenorrhea for12
months or follicle-stimulating hormone measurements (FSH)  23
UI/mL were considered postmenopausal. Perimenopause was
stablished when menstrual irregularity had occurred without any
natomic cause. Women with regular menstrual cycles were con-
idered to be premenopausal.10 We excluded from the study
hysically debilitated patients, those with a personal history of
ilateral oophorectomy, and those who used hormonal medications
o treat menopausal symptoms within 3 months before enrollment.
f the 33 women who met the inclusion criteria, 6 did not respond
o our telephone contact and 4 declined to participate in the study,
eaving 23 subjects.
Women were interviewed in the Menopause Outpatient Clinic
y the same investigator, who ascertained: age, race, education,
arital status, date of transplantation, time since transplantation,
isease that caused liver failure, type of immunosupressive drug
urrently used, history of high blood pressure or diabetes mellitus,
ate of menarche, date of last menses, menstrual pattern, and
istory of active sex life. We also measured weight (kg), height (m),
nd blood pressure (mmHg) of these women, as well as performing
general physical and gynecological examination. After the inter-
iew, the women underwent laboratory tests for aspartate amino-
ransferase (AST), alanine aminotransferase (ALT), alkaline phos-
hatase, gamma-glutamyl-transferase (GGT), and bilirubin and
one densitometry of the lumbar spine and femur. All subjects
igned a written informed consent form before the interview. The
tudy was approved by our Research Ethics Committee (number
21/2008) and financed by FAPESP (number 2008/09726-6).
Bone Mineral Density
Bone mineral density was measured at the lumbar spine (L1–L4),
total femur and femoral neck using dual energy x-ray absorptiom-
etry (DXA; Hologic, Discovery, Wisc). The effective coefficient of
variation (CV) of the device is 0.45%. Bone mineral density
measurements were expressed in grams by cm2 and as T- and
Z-scores. For the diagnosis of osteoporosis by densitometry, we used the T-score value for postmenopausal and perimenopausal
women. For premenopausal women, we used the Z-score.11 Osteo-
orosis was defined as T-score values  2.5 standard deviations.
ow bone mass was diagnosed when the T-score values measured
etween 1 and 2.5 standard deviations. Bone mass was consid-
red normal when T-score values were  1 standard deviation.12
Z-score values 2 standard deviations were considered within
the expected value and Z-scores  2 standard deviations were
classified as bone mass changes.11
Biochemical and Hormonal Measurements
Laboratory tests were drawn from 7 to 10 AM on the day of the
interview after an overnight fast. Samples were stored in a freezer
at 20°C until the tests. FSH measurement was obtained by
chemiluminescence (Advia, Centauro-Siemens), where the mini-
mum concentration detected was 0.3 mUI/mL and concentrations
 23 mUI/mL were defined as postmenopausal. AST and ALT
measurements were obtained by the kinetic UV test (Liquiform-
Labtest); alkaline phosphatase was measured by the modified
Bowers and McComb method (Liquiform-Labtest); GGT was
measured by the modified Szasz method (Liquiform-Labtest);
bilirubin by the Jendrassik method (Liquiform-Labtest).
Statistical Analysis
Data were evaluated by the mean values with standard deviations
and medians. Correlations between interval measurements were
evaluated by Spearman’s rank correlation coefficient. For labora-
tory or interval measurements, the median value was used as the
cut-off. Analysis of categories above or below the median was
performed using Fisher’s exact test and simple odds ratio (OR).
The adopted significance level was 5%; The SAS version 9.1.3
(SAS, Inco, Chicago, Ill) was the software used for the analysis.
RESULTS
The mean age of the women was 52.5 10.9 years (median,
9.2; range, 35.0–69.6). There were 4 (17.4%) of 35–40
ears of age; 1 (4.3%) of 40–45; 7 (30.4%) of 45–50; 4
17.4%) of 55–60; 3 (13%) of 60–65; and 4 (17.4%) of
5–70 years. The mean age of the women at liver transplan-
ation was 46.7  12 years (median, 44.7; range, 25.7–63.9).
he mean time since transplantation was 5.8  3.1 years
median, 5.8; range, 1–11.9). Mean body mass index was
7.0  4.6 (median, 27.3; range, 18.8–38.2). Of the 23
omen, 7 (30.4%) were premenopausal, 3 (13%) perimeno-
ausal, and 13 (56.5%) postmenopausal. Corticosteroids
ere administered for immunosuppression in 7 women
30.5%); therefore, 16 (69.5%) were not prescribed corti-
osteroids.
Of 23 women included in the study, 13 had bone mass
hanges (56.5%), including 5 (21.7%) who had osteoporosis
etected by densitometry with 3 (13%)1 site and 2 (8.7%)
n the lumbar spine, femoral neck, and total femur. Eight
ad low bone mass in 1 site (34.8%; Table 1).
Being postmenopausal was significantly associated with a
ecreased bone mass: OR, 69.0 (95% confidence interval
CI], 2.89–1647.18; P  .0001). Age at the time of liver
ransplantation showed a significant relationship. For those44 years at the time of the surgical procedure, the risk was
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POSTTRANSPLANT DECREASE IN BONE MASS 135349.50 (95% CI, 3.84–638.43; P  .0001). The age of a
oman at the time of the interview also showed a significant
orrelation. There was a higher risk of bone mass changes
hen the age was  49 years: OR, 13.33 (95% CI, 1.78–
00.15; P  .0123). Time since transplantation also had a
significant relationship to bone mass, and time after liver
transplantation 5.8 years was a protective factor against
bone mass changes: OR, 0.11 (95% CI, 0.02–0.78; P 
.0361).
All women included in the study were taking immunosu-
pressive drugs. Of these, 8 (34.8%) were prescribed tacroli-
mus and mycophenolate; 4 (17.4%), tacrolimus alone; 3
(13%) cyclosporine alone; 3 (13%), tacrolimus and predni-
sone; 1 (4.3%), cyclosporine and prednisone; 1 (4.3%),
cyclosporine and mycophenolate; 1 (4.3%), tacrolimus,
prednisone, and mycophenolate; 1 (4.3%), cyclosporine,
prednisone, and mycophenolate; and 1 (4.3%), tacrolimus,
prednisone, and azathioprine. Due to the small number of
women, the various combinations of immunosuppressive
drugs and the fact that glucocorticoids are the group of
immunosuppressants most closely related to decreased
bone mass, we subdivided the women into 2 groups; Corti-
costeroid use (30.5%), and no use of these drugs (69.5%).
No difference was observed between groups regarding bone
mass (OR, 0.18; 95% CI, 0.03–1.28; P  .1688).
Disorders responsible for transplantation were classified
into 2 groups: Cholestatic (primary biliary cirrhosis and
primary sclerosing cholangitis) and noncholestatic (the re-
maining disorders). There was no evidence of a difference
between groups regarding bone mass (OR, 0.13; 95% CI,
0.01–1.38; P  .1269). Analysis of the association between
bone mass and liver enzyme levels (AST, ALT, alkaline
phosphatase, and GGT) and bilirubine also failed to show
any difference. There were no associations between bone
mass and race, education, marital status, arterial hyperten-
sion, presence of diabetes, age at menarche, sexual activity,
body mass index, or parity (Table 2).
To quantify a correlation between variables in which we
observed a significant association we used Spearman’s
Table 1. Bone Mineral Density According to WHO Criteria
(n  23)
Measurement Site n %
Lumbar spine (L1–L4)
Osteoporosis (T score  2.5) 4 17.4
Low bone mass (T score from 1 to 2.5) 8 34.8
Normal (T score from 1 to 1/Z-score until 2) 11 47.8
emoral neck
Osteoporosis (T score  2.5) 3 13.0
Low bone mass (T score from 1 to 2.5) 9 39.1
Normal (T score from 1 to 1/Z-score until 2) 11 47.8
otal femur
Osteoporosis (T score  2.5) 2 8.7
Low bone mass (T score from 1 to 2.5) 7 30.4
Normal (T score from 1 to 1/Z-score until 2) 14 60.9
WHO, World Health Organization.correlation coefficient. There was an inverse correlation ibetween the total lumbar spine bone mineral density in
grams per square centimeter and present chronological age
(P  .01; R  0.58); age at the time of transplantation
(P  .01; R  0.66); and time since onset of menopause
expressed in months after the last menses (P  .01; R 
0.62). There was a direct correlation between total lumbar
spine bone mineral density in grams per square centimeter
and time since transplantation (P  .02; R  0.45; Fig 1)
DISCUSSION
The purpose of this study was to evaluate bone mass as well
as factors associated among liver transplanted women aged
 35 years. We observed a decreased bone mass in 56.5%
of the subjects: 34.8% with a low bone mass and 21.7% with
osteoporosis. The prevalence of observed bone mass
changes agreed with previously reported data, which de-
scribed bone mass changes in 65.5% of cases13 and osteo-
orosis among 25% to 50% of women receiving a liver
ransplantation.14,15
We observed a significant association of older patient age
at the time of liver transplantation with a low bone mass.
Regarding age at transplantation, previous studies have
reported an inverse relationship between bone mass and
chronological age before the performance of the surgical
procedure.16,17 Low bone density before transplantation
proved to be the major risk factor for the development of
osteoporosis and pathologic fractures after surgery.18 In
ontrast, Guichelaar et al16 described younger age and
aving greater bone mass before surgery as risk factors for
reater bone loss in the first 4 months posttransplantation.
owever, despite greater bone loss, this group of patients
id not develop densitometry values compatible with low
one mass after undergoing liver transplantation. The study
roup of Guichelaar et al16 was heterogeneous including
oth men and women of various age groups. Therefore, a
omparison between their results and ours is hampered.
The relationship between menopausal status and bone
ass is yet to be clarified among patients with chronic liver
isease. In the present case study, 30.4% of the patients
ere premenopausal, 13% were perimenopausal, and
6.6% were postmenopausal. In perimenopausal and post-
enopausal women, we observed an 81.2% rate of bone
ass change, including 50% with low bone mass and 31.2%
ith osteoporosis.
In this study, the rate of low bone mass in climacteric
omen undergoing liver transplantation was similar to that
eported in women not undergoing a liver transplantation,
hich is estimated to be 37%–50%.19 The rate of osteopo-
osis observed among transplanted climacteric recipients
as similar to that observed in the postmenopausal popu-
ation with no liver disease, namely approximately 30%.20
In the present study, the prevalence of osteoporosis in
climacteric patients undergoing a liver transplantation was
lower than that reported by Isoniemi et al,15 who described
steoporosis in 50% of postmenopausal patients undergo-
ng liver transplantation. However, it is worth mentioning
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1354 BACCARO, BOIN, PEDRO ET ALthat in the study of Isoniemi et al,15 approximately 94% of
climacteric women who underwent liver transplantation
were prescribed glucocorticoids, in contrast to the only 19%
in the present study.
We confirmed an inverse correlation between bone min-
eral density and time since amenorrhea as expressed in
months after the last menstrual period; that is, the longer
time since the onset of menopause, the lower the bone
mineral density. Monegal et al2 observed correlations be-
ween menopausal status and chronological age, but this
ariable did not significantly influence bone mass. In a study
f nontransplanted patients with primary biliary cirrhosis,
uanabens et al8 concluded that menopausal status was
ot, although chronological age, severity of liver disease,
dvanced histologic stage, and low body mass index, were
ndependent risk factors for osteoporosis.
In the present study, none of the premenopausal women
Table 2. Factors Associated With Bone Mass Chang
Bone Ma
Changed
n %
Age (y)
49 3 23.1
49 10 76.9
Race
White 11 84.6
Non-white 2 15.4
ypertension
Yes 1 7.7
No 12 92.3
iabetes mellitus
Yes 4 30.8
No 9 69.2
enopausal status
Premenopausal 0 0.0
Perimenopausal 2 15.4
Menopausal 11 84.6
enarche (y)
13 5 38.5
13 8 61.5
ime since transplantation (y)
5.8 9 69.2
5.8 y 4 30.8
ge at transplantation (y)
44 2 15.4
44 y 11 84.6
MI (kg/m2)
27 7 53.8
27 6 46.2
mmunosuppression
Without corticosteroids 11 84.6
With corticosteroids 2 15.4
iver disease
Cholestatic 1 4.3
Others 12 52.2
*Fisher’s Exact Test.ndergoing liver transplantation displayed bone mass changes, a finding in agreement with the results of Guiche-
aar et al,16 which indicated a gain in bone mass during the
rst 2 years after transplantation that was significantly
igher among premenopausal than perimenopausal and
ostmenopausal patients, probably owing to the high estro-
en levels in the latter groups of women. However, there is
scarcity of studies to elucidate more clearly the role of
ypoestrogenism in bone mass changes after liver trans-
lantation.
Previous data have shown that the loss of bone mass
ccurs mainly in the first 3–6 months after liver transplan-
ation owing to an uncoupling between bone formation and
one resorption.2,16,18 Bone histology studies have de-
scribed that bone loss ceases approximately 6 months after
liver transplantation. Bone formation tended to increase,
especially in the lumbar spine, resulting in the recovery of
bone mass within 2 years after the procedure.2 Our study
Women Undergoing Liver Transplantation (n  23)
P-Value OR (95% CI)
Unchanged
%
.0123*
80.0 1.0
20.0 13.33 (1.78–100.15)
1.0000*
90.0 0.61 (0.05–7.88)
10.0 1.0
.5596*
20.0 0.33 (0.03–4.32)
80.0 1.0
.3394*
10.0 4.00 (0.37–43.14)
90.0 1.0
.0001*
70.0 1.0
10.0 25.00 (0.75–833.00)
20.0 69.00 (2.89–1647.18)
.2138*
70.0 1.0
30.0 3.73 (0.65–21.58)
.0361*
20.0 1.0
80.0 0.11 (0.02–0.78)
.0001*
90.0 1.0
10.0 49.50 (3.84–638.43)
.6802*
40.0 1.0
60.0 0.57 (0.11–3.04)
.1688*
50.0 1.0
50.0 0.18 (0.03–1.28)
.1269*
17.4 0.13 (0.01–1.38)
26.1 1.0es in
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POSTTRANSPLANT DECREASE IN BONE MASS 1355clear tendency for an increased bone mass in the lumbar
spine with time. A longer time after transplantation corre-
sponded to a higher bone mass. In contrast, we noticed a
less close correlation between bone mass and time since
transplantation in the femur. Previous studies had sug-
gested the same observation, concluding that the recovery
of bone mass occurred more slowly in the femoral neck than
in the lumbar spine, probably because cortical bone needs
more time to recover than trabecular bone.2,13
The deleterious effects of glucocorticoids on bone mass
have already been demonstrated.21–29 In this study, the
urrent use of corticosteroids as an immunosuppressive
rug did not affect the bone mass, probably owing to the
ime elapsed since liver transplantation. Similar results
ere also obtained in previous studies.2,13,16 An explanation
or this finding may be that high corticosteroid doses are
sed mainly in the first months posttransplantation, produc-
ng a higher loss of bone mass at that time.26 In the near
future, the doses of glucocorticoids will tend to decrease,
for combinations with tacrolimus28,30 have lessened the
necessity of glucocorticoid treatment.
Cholestatic diseases were associated with a greater prev-
alence of osteoporosis among patients who were not liver
transplant recipients.31 Malabsorption of calcium and vita-
in D, in addition to the interference of bilirubin levels in
steoblast function have been cited as risk factors.7 Analysis
of women with pretransplantation cholestatic disorders was
also performed to investigate whether these women were at
higher risk for bone mass changes after transplantation.
However, no differences were observed, probably because
of the small number of cases in our study. The nature of this
Fig 1. Correlation between lumbar bone mass and age, time sstudy did not permit the establishment of a cause and effectelationship. We also measured liver enzymes and bilirubin
o confirm whether their increase could influence bone
ass in these women. The results were not significant,
robably owing to the same limitations.
We highlight that this study evaluated only women older
han 35 years. The group was heterogeneous concerning
enopausal status and other characteristics. Therefore,
hese results should not be generalized to other liver
ransplant groups. However, we believe that the evaluation
f a group of liver transplant recipients consisting of only
omen is crucial for an enhanced understanding of post-
ransplant hypogonadism and its interference with bone
ass. We believe that in the near future the results of this
nitiative will contribute toward a broader understanding of
he need to focus on the female population, who deserve a
etter quality of life.
This study showed that menopausal status, older chrono-
ogical age at the time of transplantation, less time since
ransplantation, and older recipient age at the present time
ere the main factors associated with decreased bone mass
mong women receiving a liver transplantation. This subject
as not been well studied and is yet to be fully understood.
e believe that the data reported may help to elucidate the
ehavior of bone mass in female liver transplant recipients.
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